Next Steps in Vitiligo Therapy

In this short clip, David Rosmarin, MD, discusses the next steps and what to look for in future trials evaluating ruxolitinib cream for the treatment of vitiligo. Dr Rosmarin is the vice chair of research and education in the department of dermatology at Tufts Medical Center in Boston, MA.

Transcript

Dr Rosmarin:  There's still a lot of vs that we'll need to gather. I think it's important to still figure how ruxolitinib cream works on the different anatomical locations when we do a subgroup analysis, how it works on the elderly versus the young, how it works in different racial groups when people have more severe disease vs more a lower body surface area involvement. Plus, we also want to know if it is synergistic with phototherapy. Certainly, the phase 2 results indicated that, when we combine both phototherapy with ruxolitinib cream, that can improve response. There's still a lot of information to gather. I'm particularly excited about looking at the week 52 results because we know from the phase 2 data that repigmentation is a slow process, and we expect to see even better results and more patients achieving that F-VASI75 and T-VASI50 at the week 52 mark. A lot of exciting news is yet to come.